Natixis’s Exagen XGN Stock Holding History

Natixis’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125,000	Closed	-$1M	–	1397
2022 Q1	$1M	Hold	125,000	–	–	﹤0.01%	877
2021 Q4	$1.45M	Hold	125,000	–	–	0.01%	848
2021 Q3	$1.7M	Buy	+125,000	New	+$1.66M	0.01%	759

Other funds holding XGN

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Natixis's XGN Position: Q2 2022 in Review

Natixis sold out of Exagen (XGN) in Q2 2022, closing a stake of 125,000 shares — an estimated $1M sold.

Natixis first reported a position in XGN in Q3 2021 and held it in 3 quarters. The position peaked at $1.7M in Q3 2021. 47 funds tracked by Wall St. Rank hold XGN as of Q2 2022.

Natixis reported no remaining Exagen position as of Q2 2022 after selling out during the quarter.
Natixis sold 125,000 Exagen shares in Q2 2022, an estimated $1M.
Natixis first reported a position in Exagen in Q3 2021 and held it in 3 quarters.
Natixis's Exagen position peaked at $1.7M in Q3 2021.
47 funds tracked by Wall St. Rank held Exagen as of Q2 2022.

Based on Natixis's 13F filing for Q2 2022, filed 12 Aug 2022.